Catalyst Event
Akeso Inc (9926) · Other
From Akros SCHK HK-Korea Biotech Index (ASHKBIO)
6/3/2026, 12:00:00 AM
The company announced positive interim data from a Phase II study of Ivonescimab for first-line metastatic colorectal cancer (mCRC) at ASCO 2026, showing a 70.8% objective response rate and 100% disease control rate. Medium importance is estimated as Phase II data typically results in a 5-10% price impact scheduled.
Korean Translation
회사는 ASCO 2026에서 1차 전이성 결장직장암(mCRC)에 대한 이보시맙(Ivonescimab)의 2상 연구에서 70.8%의 객관적 반응률과 100%의 질병 통제율을 보인 긍정적인 중간 데이터를 발표함. 2상 데이터는 통상 5-10%의 주가 영향을 미치므로 5% 이상의 주가 영향이 예상됨.
Related Recent Events
Samchundang Pharm Co Ltd (000250) · Other
An extraordinary general meeting of shareholders to appoint a new outside director on June 30, 2026, scheduled. Low impact estimated as the appointment of an outside director is a routine administrative matter.
6/30/2026, 12:00:00 AM
Hansoh Pharmaceutical Group Company Limited (3692) · Other
Annual General Meeting on June 26, 2026, to approve 2025 results and dividends. Analysts estimate a 1-5% price impact for this routine corporate event scheduled.
6/26/2026, 12:00:00 AM
United Laboratories International Holdings Ltd (3933) · Other
The Annual General Meeting is scheduled for June 23, 2026, to vote on financial statements and a potential 20% share issuance mandate which could dilute existing shareholdings; high importance due to potential dilution, scheduled.
6/23/2026, 12:00:00 AM
Aimed Bio Inc (0009K0) · Other
Stock price dropped approximately 18% on June 4, 2026, reportedly due to the expiration of a post-IPO lock-up period, which led to a significant volume of shares being sold by institutional investors.
6/4/2026, 12:00:00 AM
Celltrion Inc (068270) · Trading Issue
Bonus issue of 0.05 new shares per common share. The ex-rights date was June 4, 2026, with the new shares scheduled to be listed on June 30, 2026.
6/4/2026, 12:00:00 AM
Innovent Biologics Inc (1801) · Other
Announcement that CLDN18.2 ADC IBI343 (arcotatug tavatecan) met Phase 3 primary endpoint in gastric cancer and NDA was accepted by NMPA; >10% price impact estimated due to first-in-class status expected
6/4/2026, 12:00:00 AM